Scarica l'app Stockscreener
737.71
2.51%
-19.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$756.73
Aprire:
$756.65
Volume 24 ore:
492.04K
Relative Volume:
0.68
Capitalizzazione di mercato:
$77.99B
Reddito:
$14.34B
Utile/perdita netta:
$4.50B
Rapporto P/E:
17.75
EPS:
41.5626
Flusso di cassa netto:
$3.77B
1 W Prestazione:
+0.66%
1M Prestazione:
-5.62%
6M Prestazione:
+30.82%
1 anno Prestazione:
+16.02%
Intervallo 1D:
$736.64
$759.47
Intervallo di 1 settimana:
$727.96
$761.73
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Japan’s New Dupixent Approval - simplywall.st
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Woodstock Corp - MarketBeat
Dakota Wealth Management Boosts Regeneron Pharmaceuticals Stake - National Today
Dakota Wealth Management Has $2.41 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron's 2026 Outlook: Pipeline, Weight Loss Drugs, and Post-Eylea StrategyNews and Statistics - IndexBox
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Wedge Capital Management L L P NC - MarketBeat
AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story - simplywall.st
Discipline and Rules-Based Execution in REGN Response - Stock Traders Daily
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vanguard disaggregates holdings; reports 0 shares of Regeneron (REGN) - Stock Titan
Regeneron (REGN) and Sanofi Announce Dupixent Approval in Japan to Treat Bullous Pemphigoid - insidermonkey.com
Is Regeneron a Multimillionaire-Maker Stock? - The Globe and Mail
AstraZeneca Strengthens Position In COPD Race With Successful Trials - Benzinga
Regeneron stock price forecast: consolidation likely as REGN faces resistance below recent highs - Traders Union
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Global X Japan Co. Ltd. - MarketBeat
Sarcopenia Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Oncocross, Biophytis, MyMD Pharma, Novartis, Regeneron Pharma, Merck Sharp & Dohme - StreetInsider
5 Best Debt Free Stocks to Buy Right Now - Insider Monkey
Regeneron Can't Sink Disability Bias Claims Over Scheduling - Law360
Wealth Enhancement Advisory Services LLC Has $17.54 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Hits Day Low Amid Price Pressure, Closing at $728.64 - Markets Mojo
Growth Value: Why is Regeneron Pharmaceuticals Inc stock going down2026 Rallies & Entry Point Strategy Guides - baoquankhu1.vn
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026 - The Manila Times
Regeneron sets April 29 earnings release, webcast before open - Stock Titan
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026? - TradingView
Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN
Regeneron Pharma stock faces pipeline pressure amid Dupixent sales surge and oncology setbacks - AD HOC NEWS
The Bull Case For Regeneron Pharmaceuticals (REGN) Could Change Following New Japanese Dupixent BP Approval - simplywall.st
E. Ohman J or Asset Management AB Sells 1,480 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid - WebWire
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Rep. Julia Letlow Buys Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock - MarketBeat
Avanza Fonder AB Purchases 1,590 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Assenagon Asset Management S.A. Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP) - The Manila Times
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid - The Manila Times
Press Release: Sanofi and Regeneron’s Dupixent approved in - GlobeNewswire
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment | Business Information & News | FE - Westlaw Today
Small Biotech Zips Higher On Its Regeneron-Rivaling Test Results - Investor's Business Daily
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment - Reuters
Nordea Investment Management AB Acquires 74,350 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Tokenized Stock (Ondo) price today, REGNon to USD live price, marketcap and chart - CoinMarketCap
Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality - BioSpace
How The Regeneron (REGN) Story Is Shifting As Dupixent And Pipeline Expectations Reset - Yahoo Finance
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Weak Share Momentum And Franchise Outlook - simplywall.st
Why Regeneron Pharmaceuticals (REGN) is one of the top gene therapy stocks to buy according to hedge funds - MSN
Analysts Offer Insights on Healthcare Companies: Electrocore (ECOR) and Regeneron (REGN) - The Globe and Mail
Union Bancaire Privee UBP SA Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is It Time To Revisit Regeneron (REGN) After Recent Share Price Pullback? - simplywall.st
Swiss Life Asset Management Ltd Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
CIBC Bancorp USA Inc. Makes New $10.13 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Option Exercise |
376.69 |
1,638 |
617,018 |
3,341 |
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Sale |
781.33 |
1,638 |
1,279,812 |
1,703 |
4.56%
2.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):